| Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer D Groheux, S Giacchetti, JL Moretti, R Porcher, M Espié, J Lehmann-Che, ... European journal of nuclear medicine and molecular imaging 38, 426-435, 2011 | 427 | 2011 |
| Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ... The Lancet Oncology 23 (1), 149-160, 2022 | 217 | 2022 |
| Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer D Groheux, E Hindié, M Delord, S Giacchetti, A Hamy, C de Bazelaire, ... Journal of the National Cancer Institute 104 (24), 1879-1887, 2012 | 166 | 2012 |
| Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15 J Lehmann-Che, AS Hamy, R Porcher, M Barritault, F Bouhidel, ... Breast Cancer Research 15, 1-11, 2013 | 123 | 2013 |
| Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL C Laurent, A Nicolae, C Laurent, F Le Bras, C Haioun, V Fataccioli, ... Blood, The Journal of the American Society of Hematology 135 (5), 360-370, 2020 | 122 | 2020 |
| The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study D Groheux, S Giacchetti, M Espié, L Vercellino, AS Hamy, M Delord, ... Journal of Nuclear Medicine 52 (10), 1526-1534, 2011 | 119 | 2011 |
| Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete … D Groheux, E Hindié, S Giacchetti, M Delord, AS Hamy, ... Journal of Nuclear Medicine 53 (2), 249-254, 2012 | 112 | 2012 |
| Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer AS Hamy, JY Pierga, A Sabaila, E Laas, H Bonsang-Kitzis, C Laurent, ... Annals of Oncology 28 (9), 2233-2240, 2017 | 103 | 2017 |
| Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations M Lambertini, L Ameye, AS Hamy, A Zingarello, PD Poorvu, E Carrasco, ... Journal of Clinical Oncology 38 (26), 3012-3023, 2020 | 88 | 2020 |
| Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma AS Hamy, GT Lam, E Laas, L Darrigues, T Balezeau, J Guerin, ... Breast Cancer Research and Treatment 169, 295-304, 2018 | 78 | 2018 |
| Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast … D Groheux, E Hindié, S Giacchetti, AS Hamy, F Berger, P Merlet, ... European Journal of Cancer 50 (11), 1864-1871, 2014 | 76 | 2014 |
| Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy AS Hamy, L Darrigues, E Laas, D De Croze, L Topciu, GT Lam, C Evrevin, ... PLoS One 15 (6), e0234191, 2020 | 74 | 2020 |
| Interaction between molecular subtypes and stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy AS Hamy, H Bonsang-Kitzis, D De Croze, E Laas, L Darrigues, L Topciu, ... Clinical Cancer Research 25 (22), 6731-6741, 2019 | 68 | 2019 |
| Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer D Groheux, S Giacchetti, M Delord, A de Roquancourt, P Merlet, AS Hamy, ... European journal of nuclear medicine and molecular imaging 42, 377-385, 2015 | 64 | 2015 |
| Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a … AS Hamy-Petit, L Belin, H Bonsang-Kitzis, C Paquet, JY Pierga, ... British journal of cancer 114 (1), 44-52, 2016 | 63 | 2016 |
| Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: a retrospective evaluation of subsequent pregnancies AS Hamy, R Porcher, S Eskenazi, C Cuvier, S Giacchetti, F Coussy, ... Reproductive BioMedicine Online 32 (3), 299-307, 2016 | 56 | 2016 |
| BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy AS Hamy, I Bieche, J Lehmann-Che, V Scott, P Bertheau, ... Breast cancer research and treatment 159, 499-511, 2016 | 47 | 2016 |
| Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study C De Bazelaire, R Calmon, I Thomassin, C Brunon, AS Hamy, L Fournier, ... BMC cancer 11, 1-12, 2011 | 45 | 2011 |
| Body mass index and tumor-infiltrating lymphocytes in triple-negative breast cancer G Floris, F Richard, AS Hamy, L Jongen, H Wildiers, J Ardui, K Punie, ... JNCI: Journal of the National Cancer Institute 113 (2), 146-153, 2021 | 39 | 2021 |
| Ovarian reserve in breast cancer: assessment with anti-Müllerian hormone AS Hamy, R Porcher, C Cuvier, S Giacchetti, MH Schlageter, C Coussieu, ... Reproductive BioMedicine Online 29 (5), 573-580, 2014 | 38 | 2014 |
fabien reyalInstitut Curie. Department of Surgery在 curie.fr 的电子邮件经过验证
